Rong Lisa Q, Luhmann Grant, Di Franco Antonino, Dimagli Arnaldo, Perry Luke A, Martinez Andrew P, Demetres Michelle, Mazer C David, Bellomo Rinaldo, Gaudino Mario
Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA.
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Interdiscip Cardiovasc Thorac Surg. 2024 Jul 3;39(1). doi: 10.1093/icvts/ivae129.
To determine the association of intraoperative pulmonary artery catheter (PAC) use with in-hospital outcomes in cardiac surgical patients.
MEDLINE, Embase, and Cochrane Library (Wiley) databases were screened for studies that compared cardiac surgical patients receiving intraoperative PAC with controls and reporting in-hospital mortality. Secondary outcomes included intensive care unit length of stay, cost of hospitalization, fluid volume administered, intubation time, inotropes use, acute kidney injury (AKI), stroke, myocardial infarction (MI), and infections.
Seven studies (25 853 patients, 88.6% undergoing coronary artery bypass graft surgery) were included. In-hospital mortality was significantly increased with PAC use [odds ratio (OR) 1.57; 95% confidence interval (CI) 1.12-2.20, P = 0.04]; PAC use was also associated with greater intraoperative inotrope use (OR 2.61; 95% CI 1.54-4.41) and costs [standardized mean difference (SMD) = 0.20; 95% CI 0.16-0.23], longer intensive care unit stay (SMD = 0.29; 95% CI 0.25-0.33), and longer intubation time (SMD = 0.44; 95% CI 0.12-0.76).
PAC use is associated with significantly increased odds of in-hospital mortality, but the amount and quality of the available evidence is limited. Prospective randomized trials testing the effect of PAC on the outcomes of cardiac surgical patients are urgently needed.
确定心脏手术患者术中使用肺动脉导管(PAC)与院内结局之间的关联。
检索MEDLINE、Embase和Cochrane图书馆(Wiley)数据库,查找比较术中使用PAC的心脏手术患者与对照组并报告院内死亡率的研究。次要结局包括重症监护病房住院时间、住院费用、补液量、插管时间、血管活性药物使用、急性肾损伤(AKI)、中风、心肌梗死(MI)和感染。
纳入7项研究(25853例患者,88.6%接受冠状动脉旁路移植术)。使用PAC会显著增加院内死亡率[比值比(OR)1.57;95%置信区间(CI)1.12 - 2.20,P = 0.04];使用PAC还与术中更多使用血管活性药物(OR 2.61;95% CI 1.54 - 4.41)和费用增加[标准化均数差(SMD)= 0.20;95% CI 0.16 - 0.23]、重症监护病房住院时间延长(SMD = 0.29;95% CI 0.25 - 0.33)以及插管时间延长(SMD = 0.44;95% CI 0.12 - 0.76)相关。
使用PAC与院内死亡率显著增加相关,但现有证据的数量和质量有限。迫切需要进行前瞻性随机试验,以测试PAC对心脏手术患者结局的影响。